About Us

In the United States alone, cardiovascular disease takes over 600,000 lives each year – it is responsible for one in four deaths and affects more people than all cancers combined. Countering the disease requires focus and innovation – and PhaseBio is on a mission to meet this growing need.

Our Story

The patient is at the heart of what we do.

PhaseBio is developing specialized, highly innovative therapies for patients with serious cardiovascular diseases. We are determined to overcome the lack of new treatment options for cardiovascular disease and provide superior outcomes for patients and healthcare systems. Driven by high-quality science, we leverage our team’s deep expertise to rapidly develop and commercialize our pipeline of unique medicines.

Leadership

Jonathan Mow

January 27, 2020

Chief Executive Officer

Susan Arnold, PhD

January 27, 2020

Senior Vice President, Technical Operations

Jonathan Birchall

November 18, 2021

Chief Commercial Officer

Glen Burkhardt

January 27, 2020

Senior Vice President of Human Resources

Kris Hanson

January 27, 2020

Senior Vice President and General Counsel

John Lee, MD, PhD

January 5, 2021

Chief Medical Officer

Lauren Richardson

January 5, 2021

Vice President of Regulatory and Quality

John Sharp

January 27, 2020

Chief Financial Officer

Board of Directors

Clay Thorp

January 27, 2020

Chairman

Richard van den Broek

Edmund Harrigan, MD

Nancy Hutson, PhD

William Humphries

William D. Humphries

Caroline Loewy

Jonathan Mow

January 27, 2020

Chief Executive Officer

Alex Sapir

Scientific Advisors

ELP Technology

Ashutosh Chilkoti, PhD

January 27, 2020

Theo Pilkington Professor and Chair, Department of Biomedical Engineering, Duke University

Cardiovascular Programs

Cam Patterson, MD

January 27, 2020

Chairman, Cardiopulmonary Advisory Group Chancellor, University of Arkansas for Medical Sciences

Raymond L. Benza, MD

January 27, 2020

Program Director, Advanced Heart Failure, Transplantation, Mechanical Circulatory Support and Pulmonary Hypertension at the Allegheny Health Network, Pittsburgh, PA

Robert Hamlin, DVM, PhD

January 27, 2020

Diplomate ACVIM (Cardiology/Internal Medicine) Stanton Youngberg Professorship of Veterinary Medicine, Ohio State University; Scientific Director, QTest Labs

Pradeep P.A. Mammen, MD, FACC, FAHA

January 27, 2020

Medical Director, University of Texas Southwestern Neuromuscular Cardiomyopathy Clinic

R. James White, MD, PhD

January 27, 2020

Professor of Medicine, Pulmonary Diseases and Critical Care, Pediatrics, and Pharmacology & Physiology at University of Rochester Medical Center, Rochester, NY

Ticagrelor Reversal Program

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

January 27, 2020

Executive Director of Interventional Cardiovascular Programs, Brigham and Women’s Hospital

Jeffrey I. Weitz, MD, FRCP(C), FACP, FCCP, FAHA, FACC, FESC, FCAHS

January 27, 2020

Professor of Medicine & Biochemistry, McMaster University; Executive Director, Thrombosis & Atherosclerosis Research Institute